Late Breaking Abstracts Session
Presentation during EHA2023: All Oral presentations will be presented between Friday, June 9, and Sunday, June 11 and will be accessible for on-demand viewing from Monday, June 19 until Monday, August 14, 2023, on the Congress platform.
Abstract titles and summaries were obtained from the EHA website http://www.ehaweb.org, abstracts were translated, edited, and summarized in German.
- PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA - A PHASE 2 STUDY
- TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- PHASE 3 DETERMINATION TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA - LENALIDOMIDE, BORTEZOMIB & DEXAMETHASONE (RVD) ± ASCT AND LENALIDOMIDE MAINTENANCE TO PROGRESSION
- EFFICACY AND SAFETY OF A SINGLE DOSE OF CTX001 FOR TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA AND SEVERE SICKLE CELL DISEASE
- EVOLUTIONARY LANDSCAPE OF CLONAL HEMATOPOIESIS REVEALED BY LONGITUDINAL ERROR-CORRECTED SEQUENCING IN 3359 OLDER COMMUNITY-BASED INDIVIDUALS
- HEMATOLOGICAL OUTCOMES FROM A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL OF PI3K DELTA INHIBITOR LENIOLISIB IN PATIENTS WITH ACTIVATED PI3K DELTA SYNDROME (APDS/PASLI)
- R-CODOX-M/R-IVAC VERSUS DOSE-ADJUSTED(DA)-EPOCH-R IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK BURKITT LYMPHOMA - FIRST RESULTS OF A MULTI-CENTER RANDOMIZED HOVON/SAKK TRIAL